NCT04428671View on ClinicalTrials.gov

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

October 1, 2030

Study Completion Date

October 1, 2031

Conditions
Metastatic Skin Squamous Cell CarcinomaRecurrent Skin Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Cemiplimab

Given IV

RADIATION

Radiation Therapy

Undergo standard of care radiation therapy

PROCEDURE

Therapeutic Conventional Surgery

Undergo standard of care surgery

Trial Locations (1)

30322

RECRUITING

Emory University/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER